Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 13/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.38 |
| ▸ | LGMN | Q99538 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3711628 | 0.90 | GRIA4 (0.48) | GRIA4GRIA2GRIA1GRIA3KIF11 | |
| SCHEMBL13255710 | 0.90 | GRIA4 (0.48) | GRIA4GRIA2GRIA1GRIA3KIF11 | |
| SCHEMBL6561639 | 0.86 | GRIA4 (0.51) | GRIA4GRIA1 | |
| SCHEMBL5187414 | 0.86 | CYP2C19 (0.41) | GRIA4GRIA2LGMNPTPN1GRIA1 | |
| SCHEMBL5186189 | 0.85 | GRIA4 (0.54) | GRIA4GRIA2GRIA1GRIA3KIF11 | |
| SCHEMBL13663202 | 0.84 | GRIA4 (0.43) | GRIA4GRIA2GRIA1GRIA3KIF11 | |
| SCHEMBL6155981 | 0.82 | KIF11 (0.51) | GRIA4KIF11 | |
| SCHEMBL6155942 | 0.82 | KIF11 (0.51) | GRIA4KIF11 | |
| SCHEMBL5186185 | 0.82 | GRIA4 (0.56) | GRIA4GRIA2GRIA1GRIA3KIF11 | |
| SCHEMBL5186014 | 0.82 | KIF11 (0.51) | GRIA4KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183232-B1 | MONOFLUOROALKYL DERIVATIVES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | claimed |
| US-7034045-B1 | Monofluoroalkyl derivatives | ELI LILLY AND COMPANY (US) | 2006-04-25 | — | — | US | claimed |
| JP-2002543177-A | — | — | 2002-12-17 | — | — | JP | claimed |
| EP-1183232-A2 | MONOFLUOROALKYL DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-03-06 | — | — | EP | claimed |
| WO-2000066546-A2 | MONOFLUOROALKYL DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-11-09 | — | — | WO | claimed |
| EP-1183232-B1 | MONOFLUOROALKYL DERIVATIVES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7034045-B1 | Monofluoroalkyl derivatives | ELI LILLY AND COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1330233-B1 | METHOD OF TREATING STROKE | LILLY CO ELI (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040063680-A1 | Method of treating stroke | CLEMENS JAMES ALLEN (US) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063680-A1 | Method of treating stroke | ASAH2, PCSK7, PCSK9 | GRIA4 811/4885GRIA2 1055/4885LGMN 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.